A new article details a research breakthrough that provides a promising starting point for scientists to create drugs that can cure C. diff -- a virulent health care-associated infection that causes ...

A study published by PNAS explains breakthrough research around designing drugs that target C. diff bacterial infections that result in 15,000 deaths in the U.S. annually. The bacterium is potentially ...

Clostridium difficile, a bacterium known to cause symptoms from diarrhea to life-threatening colon damage, is part of a growing epidemic for the elderly and hospitalized patients. Biologists have now ...

Am J Health Syst Pharm. 2012;69(11):933-943. Based on current clinical trials reporting fewer recurrences among patients treated with fidaxomicin in which the non-NAP1/BI/027 strains were isolated, ...

A novel combination of multiple advanced molecular imaging techniques has led to the discovery of two molecular structures, which could provide a therapeutic target for C. diff infections. “The most ...

In a major step toward a precision therapy for Clostridioides difficile (C. diff) infection, researchers at The Hospital for Sick Children (SickKids) have uncovered how the body's bile acids bind to ...

The presence of antigen-specific and neutralizing antibodies was not associated with Clostridioides difficile infection symptoms, severity, therapy approach, treatment response, or recurrences in a ...

Researchers from the University of Maryland School of Medicine and their colleagues have identified the structure of the most lethal toxin produced by certain strains of Clostridium difficile bacteria ...

A toxoid vaccine candidate against Clostridioides difficile failed to reduce the incidence of infection in at-risk adults ages 50 and older, according to results of the phase III CLOVER trial. Of ...

Data collected by researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy suggest that Clostridioides difficile, or C. diff, a bacterial ...

A study investigating samples of the superbug Clostridioides difficile across 14 pig farms in Denmark finds the sharing of multiple antibiotic-resistance genes between pigs and human patients, ...

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally, it was hard to grow in the lab, and, now, it’s the source of gut infections that are tough to treat. About half a ...